Globus Medical Company Profile (NYSE:GMED)

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical, Inc. (NYSE:GMED) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.31 by $0.02. The firm earned $155.81 million during the quarter. Globus Medical had a return on equity of 14.15% and a net margin of 18.09%. View Globus Medical's Earnings History.

Globus Medical updated its FY17 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of $1.27 for the period, compared to the Thomson Reuters consensus estimate of $1.27. The company issued revenue guidance of $625 million, compared to the consensus revenue estimate of $625.03 million.

10 equities research analysts have issued 12-month target prices for Globus Medical's shares. Their predictions range from $23.00 to $37.00. On average, they anticipate Globus Medical's stock price to reach $28.00 in the next twelve months. View Analyst Ratings for Globus Medical.

Here are some recent quotes from research analysts about Globus Medical stock:

• 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (7/12/2017)
• 2. Aegis analysts commented, "GMED reported 4Q16 non-GAAP EPS and revenues of $0.31 and $151.6 million (6.3%/6.5% cc), respectively, with EPS 2 cents short of our and consensus estimates and revenues in line with preliminary reported revenues. Gross margins for the quarter were 74.3%, down from 75.4% in 4Q15 due to one-time accounting adjustments and acquisition-related costs. Despite increasing investments, management maintained strong non-GAAP adjusted EBITDA margins of 37.7% though non-GAAP EPS fell short by 2 cents. During the call management emphasized that sales force issues are now behind them and, most importantly, that they expect to see a return to positive organic US growth in 1Q17. Management believes that this is the inflection point and is re-affirming FY2017 guidance of $625 million in revenues and $1.27 in EPS ' roughly 6.4% organic top-line growth. We believe US approval of its Excelsius GPS robot (expected by mid-year) and build out of its trauma business will provide upside to the business, where management is assuming a modest $10 million in emerging technologies contribution in 2017. We re-iterate our Buy rating and $31 TP." (2/28/2017)

Some companies that are related to Globus Medical include Kite Pharma (KITE), Valeant Pharmaceuticals International (VRX), athenahealth (ATHN), DexCom (DXCM), United Therapeutics Corporation (UTHR), Hill-Rom Holdings (HRC), Icon Plc (ICLR), Mednax (MD), Masimo Corporation (MASI), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Mallinckrodt PLC (MNK), Taro Pharmaceutical Industries (TARO), Acadia Healthcare Company (ACHC), Hikma Pharmaceuticals Plc (HKMPF), PAREXEL International Corporation (PRXL), Alere (ALR) and Bio-Techne Corp (TECH).

Globus Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include Van Berkom & Associates Inc. (2.06%), GW&K Investment Management LLC (1.50%), Marathon Asset Management LLP (0.81%), BTIM Corp. (0.39%), Russell Investments Group Ltd. (0.17%) and Meritage Portfolio Management (0.17%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Kurt Wheeler and Robert Liptak. View Institutional Ownership Trends for Globus Medical.

Globus Medical's stock was sold by a variety of institutional investors in the last quarter, including BTIM Corp., GW&K Investment Management LLC, Parametrica Management Ltd, Capital Impact Advisors LLC, US Bancorp DE, OLD National Bancorp IN, Conservest Capital Advisors Inc. and Bank of Montreal Can. Company insiders that have sold Globus Medical stock in the last year include A Brett Murphy and Anthony L Williams. View Insider Buying and Selling for Globus Medical.

Globus Medical's stock was acquired by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, Meritage Portfolio Management, RK Asset Management LLC, Russell Investments Group Ltd., Adams Diversified Equity Fund Inc., Aperio Group LLC, Legato Capital Management LLC and ING Groep NV. View Insider Buying and Selling for Globus Medical.

Shares of Globus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Globus Medical stock can currently be purchased for approximately $33.10.